Peer Reviewed Articles Stems Cells for Knee Replacements
World J Stem Cells. 2014 Nov 26; 6(five): 629–636.
Stem jail cell application for osteoarthritis in the knee articulation: A minireview
Received 2014 Jul 27; Revised 2014 Aug 31; Accepted 2014 Sep 16.
Abstract
Human knee osteoarthritis is a chronic, indolent disease that will affect an e'er increasing number of patients, especially the elderly and the obese. Information technology is characterized past degeneration of the cartilage substance inside the knee which leads to pain, stiffness and tenderness. By some estimations in 2030, only in the United States, this medical condition will burden 67 million people. While conventional treatments like physiotherapy or drugs offering temporary relief of clinical symptoms, restoration of normal cartilage function has been difficult to achieve. Moreover, in severe cases of genu osteoarthritis total human knee replacement may be required. Full knee replacements come together with high effort and costs and are not always successful. The aim of this review is to outline the latest advances in stem cell therapy for knee osteoarthritis as well equally highlight some of the advantages of stem cell therapy over traditional approaches aimed at restoration of cartilage function in the knee. In improver to the latest advances in the field, challenges associated with stem cell therapy regarding genu cartilage regeneration and chondrogenesis in vitro and in vivo are too outlined and analyzed. Furthermore, based on their critical assessment of the present bookish literature the authors of this review share their vision most the future of stalk cell applications in the handling of knee osteoarthritis.
Keywords: Multipotent adult mesenchymal stem cells, Osteoarthritis, Knee joint joint, Clinical trial
Core tip: Knee osteoarthritis is a mutual medical condition in the elderly and the obese. Despite the diverseness of available conventional treatments for this disease, in contempo years stem cell therapy has been applied in an ever increasing number of clinical cases. Therefore the aim of this review is to outline the latest advances in stem cell therapy every bit a non-pharmacologic handling for knee osteoarthritis. It besides emphasizes on some of the challenges associated with stalk cell therapy regarding knee joint cartilage regeneration and chondrogenesis in vitro and in vivo.
INTRODUCTION
Osteoarthritis (OA) of the knee is a chronic, indolent illness that affects all genders, ages and races only is known to be well-nigh common in the elderly and in obese people. A degenerative disease of the connective tissue, information technology mainly affects the articular cartilage (Effigy i)[1]. The definition of genu OA varies in reported studies and includes cocky-reported articulatio genus OA (obtained from a questionnaire), radiographic definitions of knee osteoarthritis, and symptomatic knee OA (cocky-reported joint hurting and radiographic bear witness of OA)[2]. Symptoms may include articulation hurting, stiffness and tenderness. Furthermore, as the cartilage substance decreases, the bone surface may also become afflicted. This results in development of osteophytes (os spurs) and direct bone-bone contact. In improver to the stiffness of the articulation, the patient tries to avoid hurting by minimizing joint motility, which leads to musculus atrophy and laxity of the ligaments[1-iv].
Pathophysiology of knee osteoarthritis. Comparison between a normal and diseased joint (Illustration created subsequently Felson[iii] and Buja et al[4])
The pathogenesis of knee joint OA have been linked to biomechanical and biochemical changes in the cartilage of the articulatio genus joint (east.g., disability to withstand normal mechanical stresses, limited supply of nutrients and oxygen, inadequate synthesis of extracellular matrix components, increased synthesis of tissue-destructive proteinases (matrix metalloproteinases and aggrecanases) and overall apoptosis of chondrocytes)[iv-7]. Recently, synovial inflammation has also been accredited every bit a cistron limiting knee cartilage repair. Moreover, it correlates to clinical signs of genu OA such as swelling of the knee and inflammatory hurting[seven,8]. It is believed that synovial inflammation is a response of synovial macrophages to cartilage droppings and catabolic mediators inbound the synovial cavity[8,nine].
In regards to the epidemiology of human knee OA (Tabular array 1), studies signal that genu osteoarthritis in men aged 60 to 64 is usually found in the right articulatio genus (23%) than in the left knee (xvi.3%), while distribution seems to be more evenly balanced in women of the same age (correct knee joint, 24.ii%; left knee, 24.7%)[6,10]. A multifariousness of endogenous (eastward.g., age, sex activity) and exogenous (obesity, patient'due south lifestyle) chance factors for OA have as well been outlined[two,6,11-xiv]. Recently, a number of genome wide association studies (GWAS) (due east.yard., Rotterdam GWAS[15], Tokyo GWAS[xv], Chingford Study[16]) take highlighted the significance of gene mutations (e.g., in GDF5) for the development of knee OA[15-21]. Additionally, ross-sectional studies indicate that the run a risk of knee OA is 1.9 to 13.0 times college amongst undercover coal miners when compared to a control population; presumably, due to frequent work in the kneeling or squatting position[6]. Structure workers, specially floorers, as well have a significantly elevated prevalence of articulatio genus OA[six].
Table 1
Worldwide prevalence (2005) of knee osteoarthritis
| Knee OA prevalence | |
| Europe | |
| Western | 0.1689 |
| Cardinal | 0.1889 |
| Eastern | 0.1914 |
| Asia | |
| Middle East | 0.1764 |
| South | 0.1563 |
| E | 0.1683 |
| Southeast | 0.1704 |
| Key | 0.1854 |
| Pacific | 0.1704 |
| Africa | |
| North | 0.1764 |
| Westward Sub-Saharan | 0.1574 |
| East Sub-Saharan | 0.1544 |
| Central Sub-Saharan | 0.1528 |
| South | 0.1822 |
| Australia and Oceania | |
| Australia | 0.1736 |
| Oceania | 0.1813 |
| Due north America | |
| United States and Canada | 0.1792 |
| Key America | 0.1777 |
| Caribbean | 0.1756 |
| South America | |
| Andean | 0.1751 |
| Tropical | 0.1691 |
| Southern | 0.1693 |
As of clinical diagnosis of knee OA, information technology is complex as during the physical examination of the patient information technology is needed to confirm and characterise articulation involvement, as well every bit to exclude hurting and functional syndromes linked to other causes (e.yard., inflammatory arthritis or damaged meniscus)[three,11,22]. In addition to non-surgical treatments for this condition such as physiotherapy, diet rich in vitamin D and supportive sport (east.g., swimming)[ten,23,24], at that place are several medicinal and homeopathic products on the marketplace, which hope hurting relief and a decrease in symptoms. However, researchers are keen to investigate new treatments to combat OA of the knee.
STEM Prison cell TREATMENT
Self-regeneration of the cartilage, which includes chondrocytes, ground substance (cartilage matrix) and elastin fibers, is a slow procedure which results in new cartilage substance that is not stable for intensive burdens. The fluid inside the joint contains mesenchymal stem cells (MSCs) which tin differentiate into chondrocytes, but new deposited cartilage is very fragile and can be destroyed past applying a minimal amount of stress on the joint. Additionally in that location is only a limited quantity of MSCs in the articulation available to differentiate and the process of differentiation is dull[ane,25].
Stalk CELL Direction
The aim in using stem cells is to support the cocky-healing procedure of the human knee articulation cartilage which results in relief from OA symptoms[26-32]. This treatment should be used in conjunction with additional treatment in social club to amend patients' functional status and quality of life. Nonetheless, osteoarthritis cannot be cured by whatsoever radical handling at the moment.
The stem jail cell candidates for use in these therapies are multipotent adult MSCs, because they are bachelor in several tissues, including in the fluid inside the joint, and accept the ability to differentiate into cells of the chondrogenic lineage[33,34]. Pittenger et al[35] accept described that MSCs could exist cultured without losing their multilineage differentiation potential and information technology has been shown that MSCs are capable of undergoing chondrogenic differentiation both in-vitro and in-vivo. MSCs can exist harvested from bone marrow, periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle and deciduous teeth[36]. Regardless of their origin they have the capacity to differentiate into many jail cell types, including cells of connective tissue lineages, including bone, fat, cartilage and muscle[26,37]. MSCs were first identified in the pioneering studies of Friedenstein and Petrakova (1966)[33] and are of major involvement of research in the treatment of arthritis, in particular OA.
Multipotent adult mesenchymal stem cells are extensively investigated - in item their behaviour in prison cell civilization: how practise they stay multipotent afterwards several passages; how is chondrogenesis triggered in MSCs[32]. In that location are no definitive markers identified for MSCs nonetheless, but the immunophenotype is positive for the proteins and enzymes STRO-1, CD73, CD146, CD105, CD106, CD166 and negative for CD11b, CD45, CD34, CD31 and CD117. These are the nearly reliable for characterizing MSCs[34,36].
In that location are several other criteria which must be considered when growing MSCs in civilisation. One of the most crucial criteria is the availability of characterized factors which stimulate the anabolic activeness in cartilage including transforming growth cistron (TGF)-β, os morphogenetic poly peptide (BMP), fibroblast growth factors (FGF), insulin growth cistron (IGF)-1, hedgehog (hh) and Wingless (Wnt) proteins[26]. These factors are signalling proteins that belong to the tyrosine kinase family unit of proteins (transmembrane proteins) that actuate several downstream processes leading to cell proliferation, survival, growth and a reduction in apoptotic signalling.
Growth factors like FGF2 or transforming growth gene beta induce a positive differentiation of MSCs[38]. Moreover, the development of methods was required to develop the cartilage phenotype without hypertrophy, fibrinogenesis or ossification. In addition, a delivery organization was devised to target cells in a lesion, only without inhibiting their chondrogenic differentiation or the integrity of repaired tissue[39].
CLINICAL TRIALS
In recent years several clinical protocols for MSCs have been tested[26-32,forty]. In general, MSC related therapeutic approaches have a significant advantage to traditional surgical approaches such every bit autologous chondrocyte transplantation: no cartilage biopsy is necessary, thus no external stress and cellular damage are practical at the donor-site articular surface[31]. Moreover, direct intra-articular injection of MSC is perceived as a technically elementary way to care for avant-garde OA of the knee[32].
Stalk cells from patients
MSCs and platelet-rich plasma are harvested from the patient to be treated thus ensuring that the patient's allowed organisation will not turn down the cells[41]. These cells are already specific for the patient's body but they have to be processed earlier intra-articular injection in the articulatio genus joint. This process includes separation of the MSCs by centrifugation and other purification steps. With the aim in mind of increasing cartilage build-upwardly, chondrogenic activity of the harvested cells has to be evaluated, as well as glycosaminoglycan and type Two collagen deposition, earlier reinjection[29]. The MSCs are tested in vitro for their power to undergo chondrogenic differentiation under the previous described conditions. Glycosaminoglycan and type Ii collagen are components of the matrix of cartilage which induces and supports the differentiation of MSCs into chondrocytes. During this procedure it is important that the joint is stressed equally little as possible because the newly differentiated cartilage is highly susceptible to damage.
In regards to recent advancements in the field, Neporent[42] mentioned several pro and contra factors for stem jail cell injection in the knee joint joint. MSCs handling offers the significant reward of a quick and relatively uneventful recovery. Furthermore the bulk of patients became ambulatory within 24 h. At that place are no reasonable arguments against treatment with the patient's stalk cells, just there are several bug that have to be considered that are likely to make it financially less attractive. Firstly, at approximately $4000 per articulatio genus for stem cell reinjection, which will non be covered by health insurance, this treatment is not for affordable by anybody. Secondly, there are several criteria for eligibility for treatment of osteoarthritis with stem cells preparations. For ane affair, the body-mass-index (BMI) should non be more than than 35. Obesity, every bit previously mentioned, is a high risk factor for OA, because of the loftier stress which results on the knee articulation. Stem cell treatment is reasonable, if information technology can exist ensured that there would exist no high stress on the articulation. Furthermore this handling is applicable only if the degeneration of the cartilage is not complete. Equally long as cartilage and joint fluid is available, stalk cells can differentiate, because of necessary factors are present in the fluid and matrix but in severe cases, with os-bone contact, stem prison cell treatment is unlikely to work. Almost important for the patient is to minimize concrete activity in the immediate period subsequently the therapy because the stress to the joint reduces the adventure of successful recovery. Furthermore information technology is likely that more than one treatment session would be required, significant a greater investment of time and money.
In addition to the intra-articular injection of MSCs, Nöth et al[32] also highlighted the employ of MSCs equally progenitor cells to engineer cartilage implants that can be used to repair chondral and osteochondral lesions, or as trophic producers of bioactive factors to initiate endogenous regenerative activities in the OA articulation.
Stalk cells from donors
Another potential source of stalk cells, which can be used in therapies, is allogeneic MSCs. They are harvested from donated human umbilical cord tissue (HUCT) after normal, good for you births where the mother has been tested for infectious diseases and has a screened medical history. These harvested MSCs are and then screened to International Blood Bank Standards (Stem Cell Found, 2012).
Umbilical cord tissue provides an abundant supply of mesenchymal stem cells avoiding the requirement to harvest stem cells by invasive procedures such as liposuction or bone marrow aspiration. There is show showing that mesenchymal stem cells from umbilical cords are more robust than those from other sources such every bit fat[43].
Blitz University Medical Center[44], 2013, described the training of MSCs harvested from donated umbilical string tissue: The cells are mixed with hyaluronan, a natural polymer that plays an important role in wound healing and deposition of cartilage, and are later re-injected into the genu joint. In addition they likewise described a two-year Stage I/IIa clinical study in which a full of 12 participants aged 18 years and older, with a torso mass index of less than 35 were enrolled. Initially, six individuals with lesions sized ii to 5 cm were recruited into the study and an boosted half dozen volunteers with lesions larger than 5 cm were enrolled subsequently. Each participant went through an eligibility screening followed by a 12-mo observation period to determine the prophylactic and efficacy of the therapy with an boosted long-term follow-up evaluation at 24 mo.
Basically both treatment protocols, both for the MSCs from the patient and from a donor, were identical. Any differences in the MSCs and in some characteristics of the cells arose due to those from the patient themselves, from fat or bone marrow, being "older" than MSCs from umbilical cord and may therefore lack potential for proliferation and/or differentiation.
CONCLUSION
In recent years the office of stalk cells in wellness and disease is a topic of loftier interest for biomedical research, especially regenerative medicine[33,45,46], including not-pharmacologic treatment of articulatio genus OA[25,xl,47], and drug discovery[48-l]. At the moment there is an increase in the number of clinical cases utilizing stem jail cell therapy for human knee OA, however, many clinical protocols are still under evolution[26,thirty,xl].
Future perspectives about clinical trials with stem cells from patients
Based on the current status of clinical investigations regarding autologous stalk prison cell therapy for OA of the human knee some authors have expressed concerns about the problems of dosing , timing of intervention, blazon of MSCs, mode and route of delivery of MSCs in clinical studies[51-56]. Therefore the demand for a gilded standard for autologous stem jail cell therapy for knee OA arises, which (hopefully) volition be the aim of future clinical trials. Some other interesting trend is the increased research interest in scaffold assisted or scaffoldless grafts of MSCs every bit a method to restore the structural and biomechanical characteristics of the OA affected knee[57-62]. MSC grafts may even prove to be a viable alternative to full articulatio genus replacement in the nearly futurity. Yet, we yet accept to wait for a 100% constructive and too low toll clinical process to exist developed.
Futurity perspectives about clinical trials with stem cells from donors
The use of human umbilical string-derived mesenchymal stem cells (hUC-MSCs) in clinical trials for handling of human knee OA faces the same challenges as clinical trials with other types of MSC in terms of stem prison cell handling[43]. In that location is too the demand for more relevant clinical data, so it would be benign to have more clinical trials for knee joint OA, which utilize hUC-MSCs.
Futurity perspectives about basic enquiry in knee cartilage regeneration and chondrogenesis in vitro and in vivo
Nowadays basic research in chondrogenesis in vitro and in vivo is primarily focus on increasing the efficacy of stem cells in terms of tissue repair[57-62]. However, the issues of stalk cell characterization and tumorigenesis in vivo are somewhat overlooked.
Until relatively recently, the genomic contour of the stem cell lines maintained in vitro was only assessed in terms of ploidy and karyotype, as information technology was known that cultured cells may exhibit loss or gain of chromosome fragments or whole chromosomes and/or genomic rearrangements[63-65]. After the introduction of the concept for private capacity for DNA repair and for maintenance of genomic integrity in research and diagnostic practice, its applicability as a complex marker for the proliferative potential and/or the differentiation capacity of undifferentiated cells has been extensively discussed[66-69]. Some authors have brash that the minimal panel for characterisation of in vitro maintained pluripotent cell lines ought to include markers for individual chapters for repair of genotoxic impairment and maintenance of genomic integrity[69-71]. Some stalk cells types (mesenchymal stem cells, haematopoietic cells from bone marrow and iPSC) have been shown to lose TP53 gene copies during in vitro culturing (detected every bit loss of heterozygocity for markers at the TP53 locus)[72]. Shetzer et al[72] also reported that the cells with loss of heterozygocity were generally identified every bit the origin of the teratoma-like tumours developing later on the cells were transplanted in mice.
All those findings in basic stem jail cell biology will likely influence the development of more avant-garde (in terms of cell characterization) stem jail cell culturing and differentiation protocols and lead to the development of a gold standard in clinical trials with MSCs.
Conclusion
In conclusion, stalk cell therapy may not become a standard treatment for knee OA till the terminate of the decade due to diverse aspects regarding the clinical prophylactic (e.g., chance of complications afterwards surgery, compatibility of donor stem cells) and the affordability of this handling for the full general public. Moreover, in that location is all the same no sufficient amount of clinical data on the effectiveness of stalk cell therapy when compared with pharmacological treatments for this item disease[47]. At that place is too the emerging application of nutraceuticals as a possible alternative to drugs for knee osteoarthritis[73,74]. So here comes the question: what volition future clinical trials for human knee OA and OA in general evaluate: novel pharmaceuticals, novel nutraceuticals, improved stem cell therapies?
Footnotes
P- Reviewer: Chen YK, Fenichel I, Yao YC, Zhai K S- Editor: Tian YL Fifty- Editor: A Due east- Editor: Lu YJ
References
1. Gupta PK, Das AK, Chullikana A, Majumdar Every bit. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Jail cell Res Ther. 2012;3:25. [PMC free article] [PubMed] [Google Scholar]
ii. Chaganti RK, Lane NE. Risk factors for incident osteoarthritis of the hip and human knee. Curr Rev Musculoskelet Med. 2011;4:99–104. [PMC free article] [PubMed] [Google Scholar]
3. Felson DT. Clinical practice. Osteoarthritis of the genu. N Engl J Med. 2006;354:841–848. [PubMed] [Google Scholar]
4. Buja LM, Krüger GRF. Netter's Illustrated Homo Pathology. 2d ed. Suite, PA: Elsevier Inc; 2014. p. 390. [Google Scholar]
5. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practise. Lancet. 2011;377:2115–2126. [PubMed] [Google Scholar]
vi. Michael JW, Schlüter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the genu. Dtsch Arztebl Int. 2010;107:152–162. [PMC free commodity] [PubMed] [Google Scholar]
7. Lories RJ, Luyten FP. The os-cartilage unit in osteoarthritis. Nat Rev Rheumatol. 2011;seven:43–49. [PubMed] [Google Scholar]
viii. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625–635. [PubMed] [Google Scholar]
9. Heinegård D, Saxne T. The role of the cartilage matrix in osteoarthritis. Nat Rev Rheumatol. 2011;7:50–56. [PubMed] [Google Scholar]
10. March Fifty, Hoy D, Smith E, Blyth F, Cantankerous Grand, Fransen M, Sanchez Riera L, Vos T, Buchbinder R, Brooks P, et al. Global Burden of Disease (GBD) 2010. Bone & Joint Decade 2010- Global Alliance for Musculoskeletal Health Globe Network Conference 2012. Cited. Suite, PA: Elsevier Inc; 2020. pp. 2014–07-20. Available from: http: //bjdonline.org/wp-content/uploads/2013/03/L-March_BJD-GLOBAL-NETWORK_Global-Burden-MSK-1990-20101.pdf. [Google Scholar]
xi. Pelletier JM, Pelletier JP, editors . Agreement Osteoarthritis from Bench to Bedside. Kerala, Republic of india: Enquiry Signpost; 2011. pp. 1–26. [Google Scholar]
12. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman Advertizement, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, et al. Inability-adapted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Brunt of Disease Study 2010. Lancet. 2012;380:2197–2223. [PubMed] [Google Scholar]
13. Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau Due south. The brunt of musculoskeletal atmospheric condition. PLoS One. 2014;9:e90633. [PMC free article] [PubMed] [Google Scholar]
14. Wong R, Davis AM, Badley E, Grewal R, Mohammed Thousand. Prevalence of Arthritis and Rheumatic Diseases around the World. A Growing Burden and Implications for Health Intendance Needs (April 2010). Arthritis Community Research and Evaluation Unit, 2010. Cited 2014-07-22. Bachelor from: http: //www.modelsofcare.ca/pdf/10-02.pdf.
15. Loughlin J. Osteoarthritis year 2010 in review: genetics. Osteoarthritis Cartilage. 2011;nineteen:342–345. [PubMed] [Google Scholar]
xvi. Aref-Eshghi East, Zhang Y, Hart D, Valdes AM, Furey A, Martin G, Dominicus G, Rahman P, Arden N, Spector TD, et al. SMAD3 is associated with the total burden of radiographic osteoarthritis: the Chingford study. PLoS One. 2014;9:e97786. [PMC free article] [PubMed] [Google Scholar]
17. Wu Ten, Kondragunta 5, Kornman KS, Wang HY, Duff GW, Renner JB, Jordan JM. IL-1 receptor antagonist factor as a predictive biomarker of progression of knee osteoarthritis in a population accomplice. Osteoarthritis Cartilage. 2013;21:930–938. [PMC complimentary article] [PubMed] [Google Scholar]
eighteen. Valdes AM, Spector TD. The genetic epidemiology of osteoarthritis. Curr Opin Rheumatol. 2010;22:139–143. [PubMed] [Google Scholar]
xix. Hochberg MC, Yerges-Armstrong L, Mitchell BD. Osteoarthritis susceptibility genes continue trickling in. Lancet. 2012;380:785–787. [PMC costless article] [PubMed] [Google Scholar]
20. Valdes AM, Spector TD. Genetic epidemiology of hip and articulatio genus osteoarthritis. Nat Rev Rheumatol. 2011;7:23–32. [PubMed] [Google Scholar]
21. Sandell LJ. Etiology of osteoarthritis: genetics and synovial joint development. Nat Rev Rheumatol. 2012;8:77–89. [PubMed] [Google Scholar]
22. Paradowski PT. Osteoarthritis of the Articulatio genus: Assessing the Illness. Editorial Health Care: Current Reviews. 2014;2:e103. [Google Scholar]
23. Riecke BF, Christensen R, Christensen P, Leeds AR, Boesen M, Lohmander LS, Astrup A, Bliddal H. Comparing two low-energy diets for the treatment of articulatio genus osteoarthritis symptoms in obese patients: a pragmatic randomized clinical trial. Osteoarthritis Cartilage. 2010;xviii:746–754. [PubMed] [Google Scholar]
24. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, et al. Effects of intensive diet and exercise on human knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with genu osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310:1263–1273. [PMC free article] [PubMed] [Google Scholar]
25. Kon Due east, Filardo Grand, Roffi A, Andriolo L, Marcacci M. New trends for knee cartilage regeneration: from prison cell-costless scaffolds to mesenchymal stem cells. Curr Rev Musculoskelet Med. 2012;5:236–243. [PMC gratis commodity] [PubMed] [Google Scholar]
26. Barry FP, Murphy JM. Mesenchymal stalk cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36:568–584. [PubMed] [Google Scholar]
27. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem prison cell therapy for knee osteoarthritis. Preliminary report of 4 patients. Int J Rheum Dis. 2011;14:211–215. [PubMed] [Google Scholar]
28. Vinatier C, Bouffi C, Merceron C, Gordeladze J, Brondello JM, Jorgensen C, Weiss P, Guicheux J, Noël D. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal stalk prison cell therapy. Curr Stem Cell Res Ther. 2009;four:318–329. [PMC gratuitous article] [PubMed] [Google Scholar]
29. Murphy JM, Dixon G, Beck South, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stalk cells from patients with avant-garde osteoarthritis. Arthritis Rheum. 2002;46:704–713. [PubMed] [Google Scholar]
xxx. Koelling S, Miosge N. Stem cell therapy for cartilage regeneration in osteoarthritis. Proficient Opin Biol Ther. 2009;9:1399–1405. [PubMed] [Google Scholar]
31. Mobasheri A, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M. Mesenchymal stem cells in connective tissue technology and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. Histol Histopathol. 2009;24:347–366. [PubMed] [Google Scholar]
32. Nöth U, Steinert AF, Tuan RS. Engineering science insight: adult mesenchymal stalk cells for osteoarthritis therapy. Nat Clin Pract Rheumatol. 2008;four:371–380. [PubMed] [Google Scholar]
33. Chamberlain G, Play a trick on J, Ashton B, Middleton J. Concise review: mesenchymal stalk cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–2749. [PubMed] [Google Scholar]
34. Kolf CM, Cho East, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, cocky-renewal and differentiation. Arthritis Res Ther. 2007;9:204. [PMC free article] [PubMed] [Google Scholar]
35. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig Southward, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Scientific discipline. 1999;284:143–147. [PubMed] [Google Scholar]
36. Chen FH, Rousche KT, Tuan RS. Engineering Insight: adult stem cells in cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol. 2006;two:373–382. [PubMed] [Google Scholar]
37. Baghaban Eslaminejad Thou, Malakooty Poor E. Mesenchymal stem cells as a strong cell source for articular cartilage regeneration. World J Stalk Cells. 2014;6:344–354. [PMC free article] [PubMed] [Google Scholar]
38. Im GI, Jung NH, Tae SK. Chondrogenic differentiation of mesenchymal stem cells isolated from patients in late machismo: the optimal weather condition of growth factors. Tissue Eng. 2006;12:527–536. [PubMed] [Google Scholar]
39. Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Nöth U. Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Res Ther. 2007;ix:213. [PMC gratuitous article] [PubMed] [Google Scholar]
40. Diekman BO, Guilak F. Stem jail cell-based therapies for osteoarthritis: challenges and opportunities. Curr Opin Rheumatol. 2013;25:119–126. [PMC complimentary commodity] [PubMed] [Google Scholar]
41. Wolfstadt JI, Cole BJ, Ogilvie-Harris DJ, Viswanathan Southward, Chahal J. Current Concepts: The Function of Mesenchymal Stem Cells in the Management of Knee Osteoarthritis. Sports Health: A Multidisciplinary Approach; 2014. [PMC free commodity] [PubMed] [Google Scholar]
42. Neporent 50 Stem Cells: Alternative to Knee Replacement? Cited 2014-07-23. Available from:http: //stemcellarts.com/stalk-cells-alternative-to-knee-replacement/
43. Fan CG, Zhang QJ, Zhou JR. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Jail cell Rev. 2011;7:195–207. [PubMed] [Google Scholar]
44. Stalk cell therapy to repair damaged knee cartilage Rush University Medical Centre. Cited: 2014-01-24. Bachelor from : URL: http: //www.sciencedaily.com/releases/2013/01/130124163246.htm [Google Scholar]
45. Krampera One thousand, Pizzolo Thousand, Aprili K, Franchini K. Mesenchymal stem cells for os, cartilage, tendon and skeletal muscle repair. Bone. 2006;39:678–683. [PubMed] [Google Scholar]
46. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol. 2011;13:497–505. [PMC gratuitous article] [PubMed] [Google Scholar]
47. Singh JA. Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the time to come agree? BMC Med. 2012;10:44. [PMC free article] [PubMed] [Google Scholar]
48. Zhelev N, Trifonov D, Wang South, El Serafi I, Mitev V. From Roscovitive to CYC 202 to Seliciclib – from bench to bedside: discovery and development. BioDiscovery. 2013;10:one. [Google Scholar]
49. Zhelev N, Tummala H. Trifonov D., D' Ascanio I., Oluwaseun O.A., Fischer P.M. Contempo advances in the development of cyclin-dependent kinase inhibitors every bit new therapeutics in oncology and cardiology. Curr Opin Biotech. 2013;24:25. [Google Scholar]
50. Trifonov D, Tummala H. Clements Southward., Zhelev N. Consequence of roscovitine on cardiac hypertrophy in human stem prison cell derived cardiomyocytes. Curr Opin Biotech. 2013;24:114. [Google Scholar]
51. Viswanathan Southward, Gómez-Aristizábal A. Review of Patents and Commercial Opportunities Involving Mesenchymal Stromal Cells (MSCs) Therapies in Osteoarthritis. Recent Patents on Regenerative Medicine. 2014;iv:1–15. [Google Scholar]
52. Wei CC, Lin AB, Hung SC. Mesenchymal stem cells in regenerative medicine for musculoskeletal diseases: bench, bedside, and industry. Cell Transplant. 2014;23:505–512. [PubMed] [Google Scholar]
54. Guérit D, Maumus 1000, Apparailly F, Jorgensen C, Noël D. Therapeutic mesenchymal stem or stromal cells in rheumatic diseases: rationale, clinical information and perspectives. J Clin Invest. 2011;ane:1269–1277. [Google Scholar]
55. Wang West, Cao W. Treatment of osteoarthritis with mesenchymal stem cells. Sci China Life Sci. 2014;57:586–595. [PubMed] [Google Scholar]
56. Montoya F, Martínez F, García-Robles M, Balmaceda-Aguilera C, Koch 10, Rodríguez F, Silva-Álvarez C, Salazar Thou, Ulloa V, Nualart F. Clinical and experimental approaches to genu cartilage lesion repair and mesenchymal stem prison cell chondrocyte differentiation. Biol Res. 2013;46:441–451. [PubMed] [Google Scholar]
57. Hollander AP, Dickinson SC, Kafienah Westward. Stem cells and cartilage evolution: complexities of a simple tissue. Stem Cells. 2010;28:1992–1996. [PMC costless article] [PubMed] [Google Scholar]
58. Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. Scientific discipline. 2012;338:917–921. [PMC free article] [PubMed] [Google Scholar]
59. Jakobsen RB, Shahdadfar A, Reinholt FP, Brinchmann JE. Chondrogenesis in a hyaluronic acid scaffold: comparing between chondrocytes and MSC from bone marrow and adipose tissue. Knee Surg Sports Traumatol Arthrosc. 2010;18:1407–1416. [PubMed] [Google Scholar]
threescore. Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucchiarini M. Current perspectives in stem cell research for knee cartilage repair. Stem Cells Cloning. 2014;7:one–17. [PMC free commodity] [PubMed] [Google Scholar]
61. Johnstone B, Alini M, Cucchiarini Chiliad, Dodge GR, Eglin D, Guilak F, Madry H, Mata A, Mauck RL, Semino CE, et al. Tissue applied science for articular cartilage repair--the state of the art. Eur Cell Mater. 2013;25:248–267. [PubMed] [Google Scholar]
62. Musumeci G, Castrogiovanni P, Leonardi R, Trovato FM, Szychlinska MA, Di Giunta A, Loreto C, Castorina Southward. New perspectives for articular cartilage repair handling through tissue engineering science: A gimmicky review. World J Orthop. 2014;5:80–88. [PMC free article] [PubMed] [Google Scholar]
63. Arabadjiev A, Petkova R, Momchilova A, Chakarov Due south, Pankov R. Of mice and men – differential mechanisms of maintaining the undifferentiated land in mESC and hESC. Biodiscovery. 2012;three:1. [Google Scholar]
64. Lefort Northward, Feyeux Grand, Bas C, Féraud O, Bennaceur-Griscelli A, Tachdjian G, Peschanski M, Perrier AL. Human being embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat Biotechnol. 2008;26:1364–1366. [PubMed] [Google Scholar]
65. Spits C, Mateizel I, Geens M, Mertzanidou A, Staessen C, Vandeskelde Y, Van der Elst J, Liebaers I, Sermon One thousand. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol. 2008;26:1361–1363. [PubMed] [Google Scholar]
66. Hyka-Nouspikel Northward, Desmarais J, Gokhale PJ, Jones Yard, Meuth Grand, Andrews PW, Nouspikel T. Scarce DNA damage response and cell cycle checkpoints pb to accumulation of bespeak mutations in human being embryonic stalk cells. Stem Cells. 2012;30:1901–1910. [PubMed] [Google Scholar]
67. Petkova R, Chelenkova P, Georgieva E, Chakarov St. What's your poisonous substance? Impact of private repair chapters on the outcomes of genotoxic therapies in cancer. Role I – office of individual repair capacity in the constitution of risk for late-onset multifactorial disease. Biotechnol Biotec Eq. 2013;27:4208–4216. [PMC gratuitous article] [PubMed] [Google Scholar]
68. Lund RJ, Närvä E, Lahesmaa R. Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet. 2012;13:732–744. [PubMed] [Google Scholar]
69. Rocha CR, Lerner LK, Okamoto OK, Marchetto MC, Menck CF. The role of Dna repair in the pluripotency and differentiation of human stem cells. Mutat Res. 2013;752:25–35. [PubMed] [Google Scholar]
70. Chelenkova P, Petkova R, D' Ascanio I, Zhelev N, Chakarov Due south. In sickness and in health: a set of markers for individual repair chapters in risk assessment, monitoring and prognosis of human disease. Curr Opin Biotech. 2013;24:105. [Google Scholar]
71. Petkova R, Chelenkova P, Georgieva Due east, Chakarov St. What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Role 2 – information content and validity of biomarkers for private repair capacity in the assessment of outcomes of anticancer therapy. Biotechnol Biotec Eq. 2014;28:two–7. [PMC free commodity] [PubMed] [Google Scholar]
72. Shetzer Y, Kagan S, Koifman Thousand, Sarig R, Kogan-Sakin I, Charni K, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Prison cell Expiry Differ. 2014;21:1419–1431. [PMC free article] [PubMed] [Google Scholar]
73. Ragle RL, Sawitzke Advertising. Nutraceuticals in the management of osteoarthritis : a critical review. Drugs Aging. 2012;29:717–731. [PubMed] [Google Scholar]
74. Akhtar North, Haqqi TM. Current nutraceuticals in the management of osteoarthritis: a review. Ther Adv Musculoskelet Dis. 2012;iv:181–207. [PMC complimentary commodity] [PubMed] [Google Scholar]
Articles from World Periodical of Stalk Cells are provided here courtesy of Baishideng Publishing Grouping Inc
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178263/
Post a Comment for "Peer Reviewed Articles Stems Cells for Knee Replacements"